p53 expression in Langerhans cell histiocytosis

被引:38
作者
Weintraub, M
Bhatia, KG
Chandra, RS
Magrath, IT
Ladisch, S
机构
[1] Childrens Natl Med Ctr, Ctr Canc & Transplantat Biol, Washington, DC 20010 USA
[2] NCI, Pediat Branch, NIH, Bethesda, MD 20892 USA
关键词
Langerhans cell histiocytosis; p53; LCH cells; CD1a; cell proliferation;
D O I
10.1097/00043426-199801000-00002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Langerhans cell histiocytosis (LCH) is a disorder of unknown etiology involving the proliferation and accumulation of cells with the phenotype of a bone marrow-derived antigen-presenting cell of the skin, the Langerhans cell. We have studied p53 expresssion, an element in the control of cell proliferation, to determine whether it plays a role in the pathogenesis of LCH. Patients and Methods: LCH lesions from 10 patients with either localized (n = 5) or multisystem disease (n = 5) were studied. p53 protein expression was assessed by immunohistochemistry, and p53 gene mutation by the single strand conformation polymorphism (SSCP) technique. Results: p53 protein expression was detected in all 10 LCH biopsy specimens examined. It was restricted to Langerhans cells (LCH cells), absent from adjacent cells, and localized to the cell nuclei. No mutations of the p53 gene were detected, nor was there abnormal expression of the p53 binding protein, mdm2. Conclusions: p53 is readily detectable in LCH cells but not in normal cells. This is either caused by an unusual mechanism (given the absence of mutations in the p53 gene and of mdm2 expression in LCH cells) or by overexpression or posttranslational changes of normal p53 in response to an as yet unidentified cellular stress, Stabilization and inactivation of p53 could lead to the uncontrolled proliferation of LCH cells, or the abnormality could lead to the induction of programmed cell death.
引用
收藏
页码:12 / 17
页数:6
相关论文
共 41 条
  • [1] [Anonymous], BUTTERWORTHS INT MED
  • [2] ABNORMAL EXPRESSION OF WILD TYPE-P53 PROTEIN IN NORMAL-CELLS OF A CANCER FAMILY PATIENT
    BARNES, DM
    HANBY, AM
    GILLETT, CE
    MOHAMMED, S
    HODGSON, S
    BOBROW, LG
    LEIGH, IM
    PURKIS, T
    MACGEOCH, C
    SPURR, NK
    BARTEK, J
    VOJTESEK, B
    PICKSLEY, SM
    LANE, DP
    [J]. LANCET, 1992, 340 (8814) : 259 - 263
  • [3] HEMIZYGOSITY OR HOMOZYGOSITY - A REQUIREMENT FOR SOME BUT NOT OTHER P53 MUTANT PROTEINS TO ACCUMULATE AND EXERT A PATHOGENETIC EFFECT
    BHATIA, K
    GOLDSCHMIDTS, W
    GUTIERREZ, M
    GAIDANO, G
    DALLAFAVERA, R
    MAGRATH, I
    [J]. FASEB JOURNAL, 1993, 7 (10) : 951 - 956
  • [4] BHATIA KG, 1992, CANCER RES, V52, P4273
  • [5] BROADBENT V, 1994, BRIT J CANCER, V70, pS11
  • [6] IMPLICATIONS OF THE P53 TUMOR-SUPPRESSOR GENE IN CLINICAL ONCOLOGY
    CHANG, FJ
    SYRJANEN, S
    SYRJANEN, K
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (04) : 1009 - 1022
  • [7] ABNORMAL EXPRESSION OF THE P53-BINDING PROTEIN MDM2 IN HODGKINS-DISEASE
    CHILOSI, M
    DOGLIONI, C
    MENESTRINA, F
    MONTAGNA, L
    RIGO, A
    LESTANI, M
    BARBARESCHI, M
    SCARPA, A
    MARIUZZI, GM
    PIZZOLO, G
    [J]. BLOOD, 1994, 84 (12) : 4295 - 4300
  • [8] CHU T, 1994, BRIT J CANCER, V70, pS4
  • [9] CHU T, 1987, LANCET, V1, P208
  • [10] THE TUMOR-SUPPRESSOR P53
    DONEHOWER, LA
    BRADLEY, A
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1155 (02) : 181 - 205